This article is a correction to:
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
Yurong Peng1†
Zhuo Li2†
Yucheng Fu1
Yue Pan1
Yue Zeng1
Junqi Liu1
Chaoyue Xiao1Yingzhe Zhang1
Yahui Su3
Guoqing Li3
Fang Wu1*- 1Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- 2The Ophthalmologic Center of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- 3XiangYa School of Public Health, Central South University, Changsha, Hunan, China
A corrigendum on
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
by Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, Xiao C, Zhang Y, Su Y, Li G and Wu F (2023) Front. Oncol. 13:1011810. doi: 10.3389/fonc.2023.1011810
In the published article, two figures (1 and 2) were accidentally omitted but were subject to peer review and included in the original submission. The figures and respective citations have been added to the original article. Figure 1 has been cited at the end of 1 Introduction and Figure 2 has been cited at the end of the 6 Discussion. The missing figure and their captions appear below.
FIGURE 1
Figure 1 Biomarkers of perioperative immunotherapy. TME, Tumor microenvironment. IL-8, interleukin-8. TGF-β, Transforming growth factor. IL-6, interleukin-6. ILT-2, Ig-like transcript 2. TLS, Tertiary lymphoid structures. TIL, tumor-infiltrating lymphocytes. EGFR, epidermal growth factor receptor. HLA, human leukocyte antigen. PD-1, programmed cell death protein 1. PD-L1, Programmed cell death ligand 1. HRD, Homologous recombination deficiency. DDR, DNA-damage response/HR, homologous recombination pathway, MMR, mismatch repair. MSI, microsatellite instability. TMB, tumor mutation burden. KMT2A/B/C, Lysine methyltransferase 2A/B/C. POLE, polymerase epsilon. DNMT3A, DNA methyltransferases 3A. BMI, body mass index. CEA, carcinoembryonic antigen. NK, natural killer cells. AKK, Akkermansia muciniphila. NK, natural killer cells. CD4, cluster of differentiation 4. CD8+, cluster of differentiation 8. Treg, regulatory T cells. DC, dendritic cells. CTL, cytotoxic T lymphocyte.
FIGURE 2
Figure 2 The Phase III clinical trials of different modes of perioperative immunotherapy for Non-Small Cell Lung Cancer. CT, chemotherapy.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: perioperative period perioperative immunotherapy, neoadjuvant therapies, immunotherapy, neoadjuvant immune monotherapy, adjuvant therapy, biomarkers, NSCLC, lung cancer
Citation: Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, Xiao C, Zhang Y, Su Y, Li G and Wu F (2023) Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Front. Oncol. 13:1163376. doi: 10.3389/fonc.2023.1163376
Received: 10 February 2023; Accepted: 20 March 2023;
Published: 29 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Peng, Li, Fu, Pan, Zeng, Liu, Xiao, Zhang, Su, Li and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fang Wu, d3VmYW5nNDQ2MUBjc3UuZWR1LmNu
†These authors have contributed equally to this work